Advanced Enzyme Technologies Q4 Results: Earnings call scheduled for Aug 12

Advanced Enzyme Technologies Limited will host a conference call for analysts and investors on August 12, 2026, to discuss its unaudited financial results for the quarter ended June 30, 2026. The session is scheduled for 04:00 PM IST, providing stakeholders with an opportunity to review the company’s performance for Q4FY26. This disclosure ensures transparency regarding the company’s financial standing ahead of any broader market analysis.

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sanjay Prakash Basantani, Company Secretary and Head – Legal, signed the intimation letter dated August 04, 2026. The information has been submitted to both BSE Limited and the National Stock Exchange of India Ltd.

Conference Call Details

The conference call aims to provide clarity on the financial metrics reported for the quarter. Investors are advised to dial in at least 5–10 minutes prior to the scheduled time to ensure connectivity.

Detail	Information
Date	August 12, 2026
Time	04:00 PM IST
Quarter Covered	Ended June 30, 2026
Regulatory Basis	SEBI LODR Regulation 30

Management Representation

Senior leadership from Advanced Enzyme Technologies will address queries during the session. The management team represented includes:

Mukund Kabra, Whole-time Director
Beni Prasad Rauka, Chief Financial Officer

Participation Instructions

Participants can join the conference via the provided dial-in numbers. International participants are required to use a specific PIN number. Pre-registration is recommended to avoid wait times.

Category	Details
Primary Dial-in Numbers	+91 86 3416 8438 / +91 86 4536 6489
International PIN	5993386#
Investor Relations Contact	Mr. Ronak Saraf
Email	ir@advancedenzymes.com
Phone	+91 86578 64146

What the Numbers Show

While specific financial figures were not included in this intimation notice, the scheduling of the call indicates the company’s commitment to regular investor communication. The focus will be on the operational and financial performance of Q4FY26, with management expected to elaborate on key drivers behind the results once the detailed financials are reviewed during the session.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.34%	+1.91%	+1.59%	+12.93%	-1.86%	-23.68%

Advanced Enzyme Technologies Limited shareholders approved the reappointment of Mukund Madhusudan Kabra as Whole-time Director and the appointment of Pradip Bhailal Shah as Independent Director at its 37th Annual General Meeting (AGM) held on July 31, 2026. The meeting also saw the reappointment of MSKA & Associates LLP as statutory auditors for a five-year term, alongside the declaration of a final dividend of ₹1.35 per equity share for FY26. These governance decisions ensure continuity in leadership and financial oversight for the enzyme manufacturer.

The detailed outcomes were disclosed in a filing with BSE Limited and National Stock Exchange of India Ltd on August 1, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The resolutions were part of the special and ordinary business items addressed during the virtual AGM, which was scrutinized by Shiv Hari Jalan & Co.

Key Appointments and Tenures

The Board sought shareholder approval for critical leadership roles to align with regulatory requirements and corporate governance standards. The following table details the specific tenures approved for the key appointees:

Position	Name	Term Duration	Effective Period
Whole-time Director	Mukund Madhusudan Kabra	5 years	April 01, 2027 to March 31, 2032
Independent Director	Pradip Bhailal Shah	5 years	Up to June 11, 2031
Statutory Auditor	MSKA & Associates LLP	5 years	From 37th AGM to 42nd AGM

Ms. Rasika Rathi was also re-appointed as a Director after retiring by rotation. The approval of these appointments ensures compliance with the Companies Act, 2013, regarding board composition and auditor rotation norms.

Auditor Reappointment Details

MSKA & Associates LLP, Chartered Accountants (FRN: 105047W/W101187), was reappointed for a second term. This term covers the period from the conclusion of the current AGM until the conclusion of the 42nd AGM, scheduled for the financial year ended March 31, 2031. The reappointment follows the mandatory process outlined in Schedule III of the SEBI LODR Regulations.

Voting Results and Shareholder Sentiment

While promoter support was near-universal, public institutional investors expressed dissent on certain governance matters. The appointment of Mr. Pradip Bhailal Shah faced 3.09% opposition in valid votes, with public institutions voting against it at a rate of 11.77%. Similarly, the remuneration approval for Ms. Manasi Kabra, an immediate relative of the Whole-time Director, saw 16.11% opposition from public institutions, though it passed with 95.61% overall support. Material related-party transactions with JC Biotech Private Limited were approved with promoter votes excluded as per Regulation 23(4) of the SEBI LODR Regulations.